The cardiovascular system is the first functional organ system to develop in the vertebrate embryo, reflecting its critical role during normal development and pregnancy. This Adverse Outcome Pathway focuses on the regulation and disruption of vasculogenesis-angiogenesis during embryonic development via disruption of the Vascular Endothelial Growth Factor (VEGF) signaling pathway. This pathway is a critical regulatory system for assembly of embryonic blood vessels. Genetic studies have shown that perturbing the VEGF signaling system can invoke varying degrees of adverse consequences, ranging from congenital angiodysplasia to fetal malformations and embryolethality. This AOP is referred to as AOP 43 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).
Disruption of VEGFR signaling leading to developmental defects
Working paper
OECD Series on Adverse Outcome Pathways
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
Working paper12 December 2023
-
12 December 2023
-
Working paper12 December 2023
-
23 October 2023
-
Working paper15 December 2022
-
Working paper15 December 2022
Related publications
-
21 November 2024
-
Report19 September 2024